BRPI0602351A - método de separação das protéinas fibrinogênio, fator xiii e cola biológica de uma fração plasmática solubilizada e de preparação de concentrados liofilizados das ditas proteìnas - Google Patents
método de separação das protéinas fibrinogênio, fator xiii e cola biológica de uma fração plasmática solubilizada e de preparação de concentrados liofilizados das ditas proteìnasInfo
- Publication number
- BRPI0602351A BRPI0602351A BRPI0602351-7A BRPI0602351A BRPI0602351A BR PI0602351 A BRPI0602351 A BR PI0602351A BR PI0602351 A BRPI0602351 A BR PI0602351A BR PI0602351 A BRPI0602351 A BR PI0602351A
- Authority
- BR
- Brazil
- Prior art keywords
- proteins
- fibrinogen
- biological glue
- solubilized
- factor xiii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
- C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
"MéTODO DE SEPARAçãO DAS PROTEìNAS FIBRINOGêNIO, FATOR XIII E COLA BIOLóGICA DE UMA FRAçãO PLASMáTICA SOLUBILIZADA E DE PREPARAçãO DE CONCENTRADOS LIOFILIZADOS DAS DITAS PROTEìNAS". A presente invenção se refere a um método de separação das proteínas fibrinogênio, Fator XIII e cola biológica de uma fração plasmática solubilizada e para a preparação de concentrados liofilizados das ditas proteinas compreendendo as etapas de: purificação cromatográfica compreendendo as etapas de carregar um trocador de ânions do tipo base fraca com a dita fração solubilizada, previamente equilibrada com um tampão de uma força iónica pré-determinada de pH alcalino, que permite reter a cola biológica, a eluição da cola biológica através do aumento da força iónica do dito tampão, e separação do FXIII do fibrinogênio através da adição a ao menos uma parte do eluato da cola biológica de ao menos um agente químico de precipitação do FXIII, e a recuperação do fibrinogênio purificado resultante contendo a solução sobrenadante, e diafiltração das soluções de fibrinogênio, da cola biológica e do FXIII ressolubilizadas, seguida por uma liofilização das ditas soluções. Refere-se também aos concentrados liofilizados das ditas proteínas capazes de serem obtidos pela condução do processo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0506640A FR2887883B1 (fr) | 2005-06-29 | 2005-06-29 | Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0602351A true BRPI0602351A (pt) | 2007-02-21 |
| BRPI0602351B1 BRPI0602351B1 (pt) | 2019-01-02 |
Family
ID=35458225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0602351A BRPI0602351B1 (pt) | 2005-06-29 | 2006-06-26 | método de separação das proteínas fibrinogênio, fator xiii e cola biológica de uma fração plasmática solubilizada e de preparação de concentrados liofilizados das ditas proteínas, e, concentrado liofilizado |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8598319B2 (pt) |
| EP (2) | EP1739093B8 (pt) |
| JP (2) | JP5177966B2 (pt) |
| AU (1) | AU2006202680B2 (pt) |
| BR (1) | BRPI0602351B1 (pt) |
| CA (1) | CA2551345C (pt) |
| DK (1) | DK1739093T3 (pt) |
| ES (1) | ES2491215T3 (pt) |
| FR (1) | FR2887883B1 (pt) |
| IL (2) | IL176406A (pt) |
| PL (1) | PL1739093T3 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2894831B1 (fr) | 2005-12-16 | 2008-02-15 | Lab Francais Du Fractionnement | Colle biologique exempte de thrombine et son utilisation comme medicament. |
| ES2595059T3 (es) | 2007-03-20 | 2016-12-27 | Csl Behring Gmbh | Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano |
| CA2728358C (en) | 2008-06-23 | 2016-06-14 | Bio-Products & Bio-Engineering Ag | Storage-stable, functionally intact fibrinogen |
| KR101804136B1 (ko) * | 2008-06-24 | 2017-12-04 | 옥타파마 아게 | 응고 인자 ｖｉｉｉ을 정제하는 방법 |
| US8945895B2 (en) | 2009-07-31 | 2015-02-03 | Baxter International Inc. | Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof |
| FR2952641B1 (fr) * | 2009-11-18 | 2012-01-13 | Lfb Biomedicaments | Procede de traitement du plasma sanguin comprenant une etape de lavage par dispersion |
| JP2013537215A (ja) | 2010-09-20 | 2013-09-30 | オクタファルマ・アーゲー | フィブリノーゲンの生産方法 |
| ES2642383T3 (es) | 2012-03-13 | 2017-11-16 | Octapharma Ag | Procedimiento mejorado de producción de fibrinógeno y fibrinógeno producido por el mismo |
| US9932388B2 (en) | 2014-11-13 | 2018-04-03 | Hemarus Therapeutics Limited | Chromatographic process for producing high purity fibrinogen and thrombin |
| GB201506117D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| GB201506113D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| WO2016198641A1 (en) | 2015-06-12 | 2016-12-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Injectable composition of factor vii and fillers |
| CN109689088A (zh) | 2016-07-06 | 2019-04-26 | 法国血液分割暨生化制品实验室 | 稳定的液体纤维蛋白原 |
| FR3061020B1 (fr) | 2016-12-22 | 2019-05-17 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Composition de fibrinogene humain |
| JP7110360B2 (ja) | 2017-10-09 | 2022-08-01 | テルモ ビーシーティー バイオテクノロジーズ，エルエルシー | 凍結乾燥方法 |
| FR3090321B1 (fr) | 2018-12-21 | 2023-07-14 | Lab Francais Du Fractionnement | Procédé de filtration du fibrinogène |
| US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
| CN111518197B (zh) * | 2020-03-30 | 2024-01-05 | 哈尔滨派斯菲科生物制药有限公司 | 一种纤维蛋白原的生产方法 |
| KR20230121373A (ko) * | 2022-02-11 | 2023-08-18 | 주식회사 녹십자 | 인자 xiii의 정제방법 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR402001A (fr) | 1908-05-02 | 1909-09-24 | Siemens Ag | Emploi du tantale pour la confection des instruments chirurgicaux |
| US4237533A (en) | 1978-12-28 | 1980-12-02 | International Business Machines Corporation | Preventing initial program load failures |
| AT359652B (de) | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
| AT359653B (de) | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| FR2618784B1 (fr) * | 1987-07-30 | 1990-04-06 | Lille Transfusion Sanguine | Concentre de proteines coagulables par la thrombine, son procede d'obtention et son utilisation a titre de colle biologique |
| DE3734923C1 (de) * | 1987-10-15 | 1989-01-26 | Biotest Pharma Gmbh | Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt |
| FR2632309B1 (fr) | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
| US5206140A (en) * | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
| US5612456A (en) * | 1988-11-14 | 1997-03-18 | Zymogenetics, Inc. | Factor XIII compositions |
| WO1993003147A1 (en) | 1991-08-07 | 1993-02-18 | Zymogenetics, Inc. | Purification of factor xiii |
| FR2686883B1 (fr) | 1992-02-04 | 1994-05-13 | Aquitaine Develop Transf Sanguin | Procede de fabrication de fibrinogene de tres haute purete, fibrinogene de tres haute purete obtenu ainsi qu'une composition pharmaceutique le contenant. |
| EP0699210A1 (en) | 1994-03-18 | 1996-03-06 | Baxter International Inc. | Topical fibrinogen complex |
| CA2195127C (en) * | 1994-07-14 | 2007-06-19 | Ruth Laub | Concentrate of fibrinogene obtained from blood plasma, process and plant for its preparation |
| ZA955492B (en) | 1994-07-18 | 1996-02-13 | Methanol Casale Sa | Catalyst-seal support device in particular for exothermic heterogeneous catalytic synthesis reactors |
| GB9424732D0 (en) * | 1994-12-08 | 1995-02-08 | Common Services Agency | Heat treated blood plasma proteins |
| US5643192A (en) * | 1995-04-06 | 1997-07-01 | Hamilton Civic Hospitals Research Development, Inc. | Autologous fibrin glue and methods for its preparation and use |
| AU3495897A (en) | 1996-07-24 | 1998-02-10 | Kimberly-Clark Worldwide, Inc. | Fibrous sheet materials containing oat extract |
| US6121232A (en) | 1997-01-31 | 2000-09-19 | Omrix Biopharmaceuticals Sa | Stabilized mixture comprising fibrinogen |
| US5981254A (en) | 1997-10-30 | 1999-11-09 | Haemacure Corporation | Process for producing thrombin from plasma |
| NZ505424A (en) * | 1998-01-23 | 2002-09-27 | Csl Ltd | Purification of fibrinogen |
| US7276235B2 (en) | 1998-11-18 | 2007-10-02 | Zlb Behring Gmbh | Tissue glue with improved antiadhesive properties |
| AU774118B2 (en) | 1999-02-12 | 2004-06-17 | Baxter Healthcare Sa | A method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method |
| US6610043B1 (en) | 1999-08-23 | 2003-08-26 | Bistech, Inc. | Tissue volume reduction |
| CA2394797A1 (en) | 1999-12-20 | 2001-06-28 | Tsuyoshi Takahashi | Process for producing virus-free plasma protein composition by porous membrane treatment, virus-free plasma protein composition and method of removing viruses |
| US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
| DE60042343D1 (de) * | 1999-12-23 | 2009-07-16 | Csl Ltd | Abtrennung von fibrinogen von plasmaproteasen |
| IL136552A (en) | 2000-06-05 | 2005-05-17 | Omrix Biopharmaceuticals Ltd | Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration |
| JP2003055257A (ja) * | 2001-08-10 | 2003-02-26 | Nihon Pharmaceutical Co Ltd | 安定な血液凝固第ｘｉｉｉ因子製剤 |
| DE10211632A1 (de) | 2002-03-15 | 2003-10-09 | Aventis Behring Gmbh | Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration |
| GB0216001D0 (en) * | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
| JP2004057029A (ja) * | 2002-07-25 | 2004-02-26 | Sysmex Corp | 可溶性フィブリンの調製方法 |
| AT501088A2 (de) * | 2002-12-18 | 2006-06-15 | Bio Prod & Bio Eng Ag | Stabile therapeutische proteine |
| ES2214967B1 (es) | 2003-03-06 | 2005-06-16 | Probitas Pharma, S.A | Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento. |
| DE102004009400A1 (de) | 2004-02-24 | 2005-09-08 | Zlb Behring Gmbh | Fibrinogen Reinigung |
| FR2866890B1 (fr) | 2004-02-27 | 2008-04-04 | Lab Francais Du Fractionnement | Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant |
| ES2595059T3 (es) | 2007-03-20 | 2016-12-27 | Csl Behring Gmbh | Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano |
-
2005
- 2005-06-29 FR FR0506640A patent/FR2887883B1/fr not_active Expired - Fee Related
-
2006
- 2006-06-19 IL IL176406A patent/IL176406A/en not_active IP Right Cessation
- 2006-06-22 AU AU2006202680A patent/AU2006202680B2/en not_active Ceased
- 2006-06-23 JP JP2006173765A patent/JP5177966B2/ja not_active Expired - Fee Related
- 2006-06-26 BR BRPI0602351A patent/BRPI0602351B1/pt not_active IP Right Cessation
- 2006-06-28 CA CA2551345A patent/CA2551345C/fr not_active Expired - Fee Related
- 2006-06-28 US US11/477,212 patent/US8598319B2/en active Active
- 2006-06-29 ES ES06013497.0T patent/ES2491215T3/es active Active
- 2006-06-29 PL PL06013497T patent/PL1739093T3/pl unknown
- 2006-06-29 DK DK06013497.0T patent/DK1739093T3/da active
- 2006-06-29 EP EP06013497.0A patent/EP1739093B8/fr active Active
- 2006-06-29 EP EP14166826.9A patent/EP2772499A1/fr not_active Withdrawn
-
2012
- 2012-11-21 JP JP2012255331A patent/JP5662988B2/ja not_active Expired - Fee Related
-
2013
- 2013-10-17 US US14/056,903 patent/US9320779B2/en active Active
- 2013-10-17 US US14/056,886 patent/US9339530B2/en active Active
-
2015
- 2015-10-06 IL IL241864A patent/IL241864A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9320779B2 (en) | 2016-04-26 |
| JP5177966B2 (ja) | 2013-04-10 |
| DK1739093T3 (da) | 2014-08-18 |
| EP1739093B8 (fr) | 2014-10-08 |
| IL176406A (en) | 2015-10-29 |
| EP1739093B1 (fr) | 2014-06-18 |
| JP2007008934A (ja) | 2007-01-18 |
| PL1739093T3 (pl) | 2014-12-31 |
| EP2772499A1 (fr) | 2014-09-03 |
| US20080207878A1 (en) | 2008-08-28 |
| US20140154231A1 (en) | 2014-06-05 |
| IL241864A0 (en) | 2015-11-30 |
| JP2013047273A (ja) | 2013-03-07 |
| EP1739093A1 (fr) | 2007-01-03 |
| CA2551345C (fr) | 2014-12-23 |
| CA2551345A1 (fr) | 2006-12-29 |
| FR2887883B1 (fr) | 2007-08-31 |
| ES2491215T3 (es) | 2014-09-05 |
| JP5662988B2 (ja) | 2015-02-04 |
| BRPI0602351B1 (pt) | 2019-01-02 |
| US9339530B2 (en) | 2016-05-17 |
| FR2887883A1 (fr) | 2007-01-05 |
| AU2006202680A1 (en) | 2007-01-18 |
| US20140148580A1 (en) | 2014-05-29 |
| AU2006202680B2 (en) | 2012-03-29 |
| US8598319B2 (en) | 2013-12-03 |
| IL176406A0 (en) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0602351A (pt) | método de separação das protéinas fibrinogênio, fator xiii e cola biológica de uma fração plasmática solubilizada e de preparação de concentrados liofilizados das ditas proteìnas | |
| JP5632376B2 (ja) | エリスロポエチンの精製 | |
| ATE470150T1 (de) | Methode zum schnellen identifizieren von kleinen organischen liganden | |
| BRPI0805838A2 (pt) | procedimento para a extração de uma proteìna presente no leite | |
| IL187293A (en) | Methods for producing glycosylation proteins at site n and host prokaryotic organisms | |
| BRPI0616712B8 (pt) | método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas | |
| WO2007064917A3 (en) | Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins | |
| CA2728047A1 (en) | A process of purifying coagulation factor viii | |
| BR0015137A (pt) | Peptìdeos antigênicos de neisseria | |
| BRPI0713252C1 (pt) | processo para a recuperação de fator de crescimento endotelial vascular (vegf) recombinante reenovelado | |
| MX348154B (es) | Anticuerpos de enlace a il-1-beta y fragmentos de los mismos. | |
| MX2012001263A (es) | Metodo para purificar adamts13 recombinante y otras proteinas y sus composiciones. | |
| WO2009004315A8 (en) | Isolated peptides and uses thereof | |
| Lee et al. | N-glycan analysis of human α1-antitrypsin produced in Chinese hamster ovary cells | |
| BR112012024956A2 (pt) | processo para a purificação de uma proteína de fator de crescimento | |
| PE20190661A1 (es) | Preparacion de derivados del factor xa | |
| MX2010001482A (es) | Proteinas de streptococcus inmunogenicas. | |
| WO2008003707A3 (en) | Minimized small peptides with high affinity for factor viii and factor viii-like proteins | |
| Piazza et al. | Identification of highly active flocculant proteins in bovine blood | |
| WO2007034210A8 (en) | Deglycosylated anti-muc-1 antibodies and uses thereof | |
| BR0208786A (pt) | Métodod para identificação de proteìnas de bactérias intracelulares | |
| CN105319116B (zh) | 基于磁性微球的蛋白质n末端肽段分离方法 | |
| ES2552337T3 (es) | Procedimientos para la preparación de plasminógeno | |
| Kumar et al. | Easy and efficient protocol for purification of recombinant peptides | |
| SE0200543D0 (sv) | Method of separation using aromatic thioether ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/01/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2625 DE 27-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |